Data

Pharmacology of polymyxins, for developing novel antibiotics against 'superbugs': data

Monash University
Dr Jian Li (Associated with, Principal investigator) Assoc Prof Denis Spelman (Associated with) Assoc Prof Philip Thompson (Associated with) Dr Ian Larson (Associated with) Dr John Boyce (Associated with)
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=1959.1/489126&rft.title=Pharmacology of polymyxins, for developing novel antibiotics against 'superbugs': data&rft.identifier=1959.1/489126&rft.publisher=Monash University&rft.description=Polymyxins are increasingly the last option available to treat patients with infections caused by antibiotic-resistant bacteria known as Gram-negative ‘superbugs'. Polymyxins were developed more than 50 years ago, before the advent of modern drug development and approval procedures. Due to a lack of clinical data, there were difficulties administering the drugs with the right dose and at the right time, with patients falling ill due to potential toxicity. The recent emergence of 'superbugs' resistant to all other antibiotics has led to a renewed interest in polymyxins. The study has involved testing (using techniques such as chromography) of samples from animals and from more than 200 patients in the US, Thailand, Brazil and Greece. Raw data from these experiments (500Gb, and around 100,000 data files in total) are used to support statistical analysis and modelling. This dataset is an output of an ongoing research program that includes a collaboration between Monash University (Prof Roger Nation, Assoc Prof Jian Li, Dr Tony Velkov, Dr Ian Larson, Prof Ben Adler, Dr John Boyce, Prof Paul Hertzog, Dr Jinhua Li), the Austin Hospital (Dr Ben Howden), the Alfred Hospital (Assoc Prof Dennis Spelman), the Women's and Children Hospital (Prof John Turnidge), St Vincent's Hospital (Assoc Prof Prue Hill), University of Pittsburgh (Dr Fernanda Silveira), University of Queensland (Prof David Paterson, Prof Matt Cooper), Mahidol University in Thailand (Prof Visanu Thamlikitkul) and the State University of New York at Buffalo (Prof Alan Forrest, Dr Brian Tsuji). More than 63 journal articles have resulted from this program of research. The World Health Organisation (WHO) has identified antibiotic resistance as one of greatest threats to human health. The dosing formula and usage guidelines arising from this research improve patient care by enabling doctors to better use antibiotics and by minimising antibiotic resistance. The data also contribute to the development of novel antimicrobial peptides that will target life-threatening 'superbugs'. Patients likely to benefit are those with bacterial infections. &rft.creator=Dr Jian Li&rft.date=2025&rft.relation=10.1128/​AAC.05191-11 &rft.relation=10.1128/​AAC.05298-11&rft.relation=10.1128/​AAC.05028-11&rft.relation=10.1371/journal.pone.0024030&rft.relation=http://dx.doi.org/10.1016/j.ijantimicag.2011.07.014&rft.relation=PCT/AU2010/000568&rft.coverage=US&rft.coverage=GR&rft.coverage=BR&rft.coverage=TH&rft_rights=All rights reserved, except by negotiation with the owers&rft_subject=Basic Pharmacology&rft_subject=MEDICAL AND HEALTH SCIENCES&rft_subject=PHARMACOLOGY AND PHARMACEUTICAL SCIENCES&rft_subject=Clinical Pharmacology and Therapeutics&rft_subject=Pharmaceutical Sciences&rft_subject=Toxicology (incl. Clinical Toxicology)&rft_subject=Pharmacology and Pharmaceutical Sciences not elsewhere classified&rft_subject=Antiobiotic resistance&rft_subject=Colistin&rft_subject=Polymyxin B&rft_subject=Gram-negative bacteria&rft_subject=Infectious diseases&rft_subject=Antibiotic discovery&rft_subject=Antimicrobial peptides&rft.type=dataset&rft.language=English Access the data
Cite Saved to MyRDA Save to MyRDA

Licence & Rights:

view details

All rights reserved, except by negotiation with the owers

Access:

Conditions apply view details

Access to raw data may be provided by negotiation. Some data will be progressively disseminated as supplements to publications. Some processed sequence data will be disseminated through appropriate open access archives or databases in future. Point of contact: [email protected] to discuss terms and conditions

Full description

Polymyxins are increasingly the last option available to treat patients with infections caused by antibiotic-resistant bacteria known as Gram-negative ‘superbugs'. Polymyxins were developed more than 50 years ago, before the advent of modern drug development and approval procedures. Due to a lack of clinical data, there were difficulties administering the drugs with the right dose and at the right time, with patients falling ill due to potential toxicity. The recent emergence of 'superbugs' resistant to all other antibiotics has led to a renewed interest in polymyxins. The study has involved testing (using techniques such as chromography) of samples from animals and from more than 200 patients in the US, Thailand, Brazil and Greece. Raw data from these experiments (500Gb, and around 100,000 data files in total) are used to support statistical analysis and modelling. This dataset is an output of an ongoing research program that includes a collaboration between Monash University (Prof Roger Nation, Assoc Prof Jian Li, Dr Tony Velkov, Dr Ian Larson, Prof Ben Adler, Dr John Boyce, Prof Paul Hertzog, Dr Jinhua Li), the Austin Hospital (Dr Ben Howden), the Alfred Hospital (Assoc Prof Dennis Spelman), the Women's and Children Hospital (Prof John Turnidge), St Vincent's Hospital (Assoc Prof Prue Hill), University of Pittsburgh (Dr Fernanda Silveira), University of Queensland (Prof David Paterson, Prof Matt Cooper), Mahidol University in Thailand (Prof Visanu Thamlikitkul) and the State University of New York at Buffalo (Prof Alan Forrest, Dr Brian Tsuji). More than 63 journal articles have resulted from this program of research.

Notes

C.100,000 data files in total; Excel and SigmaPlot spreadsheets; images (proprietary formats)

Significance statement

The World Health Organisation (WHO) has identified antibiotic resistance as one of greatest threats to human health. The dosing formula and usage guidelines arising from this research improve patient care by enabling doctors to better use antibiotics and by minimising antibiotic resistance. The data also contribute to the development of novel antimicrobial peptides that will target life-threatening 'superbugs'. Patients likely to benefit are those with bacterial infections.

Created: 2011

Data time period: 2002

This dataset is part of a larger collection

Click to explore relationships graph
Help

Related Publications

Related People

Related Grants and Projects

Spatial Coverage And Location

iso31661: US

iso31661: GR

iso31661: BR

iso31661: TH

Subjects
Antibiotic discovery | Antimicrobial peptides | Antiobiotic resistance | Basic Pharmacology | Clinical Pharmacology and Therapeutics | Colistin | Gram-negative bacteria | Infectious diseases | Medical and Health Sciences | Pharmacology and Pharmaceutical Sciences | Pharmaceutical Sciences | Pharmacology and Pharmaceutical Sciences Not Elsewhere Classified | Polymyxin B | Toxicology (Incl. Clinical Toxicology) |

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Identifiers